eli lilly weight loss drugs are 'mega-growth assets' bmo's evan seigerman says
Published 7 months ago • 1.7K plays • Length 3:56Download video MP4
Download video MP3
Similar videos
-
3:40
eli lilly's obesity drug will be a tailwind for the stock, says bmo's evan seigerman
-
5:06
eli lilly and novo can 'coexist for awhile' in the weight-loss drug space, says bmo's evan seigerman
-
6:33
eli lilly stock gains on weight loss drug that cuts type 2 diabetes risk by 94%
-
1:26
eli lilly weight loss drug for type-2 diabetes approved by the fda
-
1:24
weight loss drugs are 'huge market' for pharmaceuticals: analyst
-
3:00
eli lilly is becoming the 'goat' of obesity, says bmo's evan seigerman
-
5:10
analyst discusses weight loss drugs and why he's bullish on eli lilly
-
3:35
eli lilly stock soars on earnings, 'off-the-charts' demand for weight-loss drugs
-
1:46
eli lilly releases new form of weight loss drug zepbound for half the price to boost access, supply
-
3:32
eli lilly, novo nordisk to test weight loss drugs for children
-
11:07
eli lilly ceo talks expanding innovation past obesity drugs
-
3:05
eli lilly releases new data from potentially game-changing weight loss drug trial
-
7:33
why eli lilly is a top glp-1 stock: roundhill ceo
-
1:32
eli lilly's weight loss drug slashes the risk of developing diabetes in long-term trial
-
1:12
lawmakers propose pathway to allow medicare to cover weight-loss drugs
-
5:53
eli lilly and novo nordisk will remain leaders in the weight-loss drug market: mizuho's jared holz
-
0:55
eli lilly ceo on compounded versions of weight loss drugs
-
0:59
eli lilly ceo on why food companies haven't seen a big impact on sales
-
2:56
eli lilly to offer weight loss drug directly to qualifying customers at lower price